BioCentury | Nov 10, 2003
Tools & Techniques

Invitrogen goes Stealth

...that allow researchers to use interfering RNA throughout the discovery process. Through its purchase of Sequitur Inc....
...sense strand of double-stranded RNA that is delivered to the cell. According to Zahl, In Sequitur's...
BioCentury | Nov 10, 2003
Company News

Invitrogen, Sequitur deal

...IVGN acquired Sequitur, including its Stealth next-generation synthetic RNAi technology for target discovery and validation. Financial...
...products, which are based on synthetic short interfering RNA (siRNA). Invitrogen Corp. (IVGN), Carlsbad, Calif. Sequitur Inc....
BioCentury | Nov 4, 2003
Company News

Invitrogen buys Sequitur

...IVGN acquired Sequitur (Natick, Mass.), including its Stealth next-generation synthetic RNAi technology for target discovery and...
BioCentury | Jun 16, 2003
Company News

Intradigm, Sequitur deal

...and develop RNAi-based therapeutics. Under the deal, the companies will cross-license respective related technologies, including Sequitur's...
...technology and Intradigm's TSGV in vivo nucleic acid delivery technology. Intradigm Corp. , Rockville, Md. Sequitur Inc....
BioCentury | Jun 13, 2003
Company News

Intradigm, Sequitur RNAi deal

...Intradigm (Rockville, Md.) and Sequitur (Natick, Mass.) partnered to research and develop RNAi-based therapeutics. Under the...
...and develop RNAi-based therapeutics. Under the deal, the companies will cross-license respective related technologies, including Sequitur's...
BioCentury | Jun 2, 2003
Company News

Sequitur sales and marketing update

...in sequence-specific inhibition of gene expression. The company said its product avoids degradation by nucleases. Sequitur Inc....
BioCentury | May 26, 2003
Company News

Sequitur, P&G deal

...The companies renewed and expanded their 2001 deal for Sequitur to conduct biological screens and supply...
...areas (see BioCentury, Oct. 15, 2001). As expanded, the deal will include additional therapeutic areas. Sequitur Inc....
BioCentury | Mar 10, 2003
Company News

Sequitur, Bristol-Myers deal

...The companies extended a 2001 deal under which Sequitur is performing biological screening and supplying its...
...antisense compounds to BMY for use in the pharma company's functional genomics-based target validation efforts. Sequitur Inc....
BioCentury | Nov 25, 2002
Company News

Genentech, Sequitur deal

...Sequitur will provide antisense/RNAi compounds and methods to DNA for target validation studies. Sequitur said antisense/RNAi...
...small molecule drug targets by inhibiting gene expression. Genentech Inc. (DNA), South San Francisco, Calif. Sequitur Inc....
BioCentury | Nov 21, 2002
Company News

Genentech, Sequitur functional genomics deal

...Sequitur (Natick, Mass.) will provide antisense/RNAi compounds and methods to DNA for target validation studies. Sequitur's...
Items per page:
1 - 10 of 32
BioCentury | Nov 10, 2003
Tools & Techniques

Invitrogen goes Stealth

...that allow researchers to use interfering RNA throughout the discovery process. Through its purchase of Sequitur Inc....
...sense strand of double-stranded RNA that is delivered to the cell. According to Zahl, In Sequitur's...
BioCentury | Nov 10, 2003
Company News

Invitrogen, Sequitur deal

...IVGN acquired Sequitur, including its Stealth next-generation synthetic RNAi technology for target discovery and validation. Financial...
...products, which are based on synthetic short interfering RNA (siRNA). Invitrogen Corp. (IVGN), Carlsbad, Calif. Sequitur Inc....
BioCentury | Nov 4, 2003
Company News

Invitrogen buys Sequitur

...IVGN acquired Sequitur (Natick, Mass.), including its Stealth next-generation synthetic RNAi technology for target discovery and...
BioCentury | Jun 16, 2003
Company News

Intradigm, Sequitur deal

...and develop RNAi-based therapeutics. Under the deal, the companies will cross-license respective related technologies, including Sequitur's...
...technology and Intradigm's TSGV in vivo nucleic acid delivery technology. Intradigm Corp. , Rockville, Md. Sequitur Inc....
BioCentury | Jun 13, 2003
Company News

Intradigm, Sequitur RNAi deal

...Intradigm (Rockville, Md.) and Sequitur (Natick, Mass.) partnered to research and develop RNAi-based therapeutics. Under the...
...and develop RNAi-based therapeutics. Under the deal, the companies will cross-license respective related technologies, including Sequitur's...
BioCentury | Jun 2, 2003
Company News

Sequitur sales and marketing update

...in sequence-specific inhibition of gene expression. The company said its product avoids degradation by nucleases. Sequitur Inc....
BioCentury | May 26, 2003
Company News

Sequitur, P&G deal

...The companies renewed and expanded their 2001 deal for Sequitur to conduct biological screens and supply...
...areas (see BioCentury, Oct. 15, 2001). As expanded, the deal will include additional therapeutic areas. Sequitur Inc....
BioCentury | Mar 10, 2003
Company News

Sequitur, Bristol-Myers deal

...The companies extended a 2001 deal under which Sequitur is performing biological screening and supplying its...
...antisense compounds to BMY for use in the pharma company's functional genomics-based target validation efforts. Sequitur Inc....
BioCentury | Nov 25, 2002
Company News

Genentech, Sequitur deal

...Sequitur will provide antisense/RNAi compounds and methods to DNA for target validation studies. Sequitur said antisense/RNAi...
...small molecule drug targets by inhibiting gene expression. Genentech Inc. (DNA), South San Francisco, Calif. Sequitur Inc....
BioCentury | Nov 21, 2002
Company News

Genentech, Sequitur functional genomics deal

...Sequitur (Natick, Mass.) will provide antisense/RNAi compounds and methods to DNA for target validation studies. Sequitur's...
Items per page:
1 - 10 of 32